Home
Home
Lallemand Pharma International AG (LPI - Switzerland), a new affiliate of Lallemand dedicated exclusively to the clinical studies, registrations, marketing and sales of pharmaceutical products, was created in early 2008. It acquired the business and intellectual property rights of the drug sold under the brands Ismigen, Respibron, Bactovax and Immubron in various countries around the world.The primary objective of LPI is to develop and sell a range of bacterial lysates that Lallemand has been producing at its facility for the last 15 years. The specificity of Lallemand's lysates is that they are produced from a complete range of inactivated pathogenic bacteria that undergo a mechanical lysis. This original and unique process gives the drug a far stronger immunogenic power than other lysates presently on the market. They target respiratory infections, which are currently developing and believed to become a major cause of disease by 2020, especially chronic obstructive pulmonary desease (COP).